Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment

Introduction Unwanted drug interactions with ionic currents in the heart can lead to an increased proarrhythmic risk to patients in the clinic. It is therefore a priority for safety pharmacology teams to detect block of cardiac ion channels, and new technologies have enabled the development of automated and high-throughput screening assays using cell lines. As a result of screening multiple ion-channels there is a need to integrate information, particularly for compounds affecting more than one current, and mathematical electrophysiology in-silico action potential models are beginning to be used for this. Methods We quantified the variability associated with concentration-effect curves fitted to recordings from high-throughput Molecular Devices IonWorks® Quattro™ screens when detecting block of IKr (hERG), INa (NaV1.5), ICaL (CaV1.2), IKs (KCNQ1/minK) and Ito (Kv4.3/KChIP2.2), and the Molecular Devices FLIPR® Tetra fluorescence screen for ICaL (CaV1.2), for control compounds used at AstraZeneca and GlaxoSmithKline. We examined how screening variability propagates through in-silico action potential models for whole cell electrical behaviour, and how confidence intervals on model predictions can be estimated with repeated simulations. Results There are significant levels of variability associated with high-throughput ion channel electrophysiology screens. This variability is of a similar magnitude for different cardiac ion currents and different compounds. Uncertainty in the Hill coefficients of reported concentration-effect curves is particularly high. Depending on a compound’s ion channel blocking profile, the uncertainty introduced into whole-cell predictions can become significant. Discussion Our technique allows confidence intervals to be placed on computational model predictions that are based on high-throughput ion channel screens. This allows us to suggest when repeated screens should be performed to reduce uncertainty in a compound’s action to acceptable levels, to allow a meaningful interpretation of the data.

[1]  Gary R. Mirams,et al.  Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic risk , 2011, Cardiovascular research.

[2]  Gary R. Mirams,et al.  Evaluation of an in silico cardiac safety assay: Using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge , 2013, Journal of pharmacological and toxicological methods.

[3]  J. Nerbonne,et al.  Molecular determinants of cardiac transient outward potassium current (I(to)) expression and regulation. , 2010, Journal of molecular and cellular cardiology.

[4]  J-P Valentin,et al.  Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks. , 2008, Journal of pharmacological and toxicological methods.

[5]  H Zhang,et al.  Models of cardiac tissue electrophysiology: progress, challenges and open questions. , 2011, Progress in biophysics and molecular biology.

[6]  Yi Liu,et al.  QPatch: the missing link between HTS and ion channel drug discovery. , 2009, Combinatorial chemistry & high throughput screening.

[7]  Denis Noble,et al.  How the Hodgkin–Huxley equations inspired the Cardiac Physiome Project , 2012, The Journal of physiology.

[8]  Christine Williams,et al.  Patch clamping by numbers. , 2004, Drug discovery today.

[9]  Alfred Stett,et al.  CYTOCENTERING: a novel technique enabling automated cell-by-cell patch clamping with the CYTOPATCH chip. , 2003, Receptors & channels.

[10]  A. Hodgkin,et al.  A quantitative description of membrane current and its application to conduction and excitation in nerve , 1952, The Journal of physiology.

[11]  Alexander G. Fletcher,et al.  Chaste: An Open Source C++ Library for Computational Physiology and Biology , 2013, PLoS Comput. Biol..

[12]  D. Noble A modification of the Hodgkin—Huxley equations applicable to Purkinje fibre action and pacemaker potentials , 1962, The Journal of physiology.

[13]  Gary Gintant,et al.  An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. , 2011, Pharmacology & therapeutics.

[14]  Derek J Trezise,et al.  Population patch clamp electrophysiology: a breakthrough technology for ion channel screening. , 2007, Molecular bioSystems.

[15]  Kevin Burrage,et al.  Modeling ion channel dynamics through reflected stochastic differential equations. , 2012, Physical review. E, Statistical, nonlinear, and soft matter physics.

[16]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .

[17]  Steven J Novick,et al.  Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG. , 2013, Journal of pharmacological and toxicological methods.

[18]  Gary R. Mirams,et al.  Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing , 2012, British journal of pharmacology.

[19]  Alexander G. Fletcher,et al.  Chaste: A test-driven approach to software development for biological modelling , 2009, Comput. Phys. Commun..

[20]  B. Neagle,et al.  FLIPR: A New Instrument for Accurate, High Throughput Optical Screening , 1996 .

[21]  Gary R. Mirams,et al.  High-throughput functional curation of cellular electrophysiology models. , 2011, Progress in biophysics and molecular biology.

[22]  David Gavaghan,et al.  Considerations for the use of cellular electrophysiology models within cardiac tissue simulations. , 2011, Progress in biophysics and molecular biology.

[23]  Liudmila Polonchuk,et al.  Toward a New Gold Standard for Early Safety: Automated Temperature-Controlled hERG Test on the PatchLiner® , 2012, Front. Pharmacol..

[24]  Denis Noble,et al.  Is it time for in silico simulation of drug cardiac side effects? , 2011, Annals of the New York Academy of Sciences.

[25]  Carol S. Woodward,et al.  Enabling New Flexibility in the SUNDIALS Suite of Nonlinear and Differential/Algebraic Equation Solvers , 2020, ACM Trans. Math. Softw..

[26]  Derek J Trezise,et al.  IonWorks™ HT: A New High-Throughput Electrophysiology Measurement Platform , 2003, Journal of biomolecular screening.

[27]  Peter J. Hunter,et al.  The CellML Model Repository , 2008, Bioinform..

[28]  D. Roden,et al.  Cellular basis of drug‐induced torsades de pointes , 2008, British journal of pharmacology.

[29]  E Sullivan,et al.  Measurement of [Ca2+] using the Fluorometric Imaging Plate Reader (FLIPR). , 1999, Methods in molecular biology.

[30]  Alan Finkel,et al.  Population Patch Clamp Improves Data Consistency and Success Rates in the Measurement of Ionic Currents , 2006, Journal of biomolecular screening.

[31]  H. Mistry,et al.  An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment. , 2012, American journal of physiology. Heart and circulatory physiology.

[32]  D. Misner,et al.  Assessing hERG channel inhibition using PatchXpress. , 2007, Clinics in laboratory medicine.

[33]  Cristian Ionescu-Zanetti,et al.  IonFlux: a microfluidic patch clamp system evaluated with human Ether-à-go-go related gene channel physiology and pharmacology. , 2011, Assay and drug development technologies.

[34]  B. Small,et al.  Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. , 2006, Journal of pharmacological and toxicological methods.

[35]  Denis Noble,et al.  Novel Approaches to Assessing Cardiac Safety —Proceedings of a Workshop , 2011, Drug safety.

[36]  J. Valentin,et al.  An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk , 2010, British journal of pharmacology.

[37]  K. T. ten Tusscher,et al.  Alternans and spiral breakup in a human ventricular tissue model. , 2006, American journal of physiology. Heart and circulatory physiology.